

**Phase 1b/2 Gastric Cancer Trial on Track with Contract Research Organisation (CRO) Appointed to Conduct Trial**

---

- **Orion Clinical Services selected to fast track plans and logistics for upcoming HER-Vaxx gastric cancer human clinical trial**
- **Initial task to identify optimal international clinical trial sites**
- **Clinical trial on track to begin 2H 2015**

**Melbourne, Australia, 1 July 2015:** Imugene Limited (ASX: IMU) (Imugene), a clinical stage immuno-oncology company, has selected leading global CRO Simbec-Orion Group Limited (Simbec-Orion) to conduct Imugene's Phase 1b/2 clinical study of HER-Vaxx in patients with advanced metastatic gastro-oesophageal adenocarcinoma. The appointment follows a rigorous selection process between several competing proposals.

Simbec-Orion will plan and manage the clinical trials including identifying optimal hospitals and investigators experienced in immuno-oncology to participate in the clinical investigation of Imugene's proprietary immunotherapy HER-Vaxx.

The trial is to commence in the second half of 2015 and is titled: *A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled Comparison of IMU-131 (HER-Vaxx) HER2/neu Peptide Vaccine Plus Cisplatin and either Capecitabine or 5-Fluorouracil Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction.*

Imugene Managing Director Charlie Walker said, "This is another milestone passed as the selection of specialist CRO Orion will greatly assist the company conduct a thorough and well prepared immuno-oncology clinical trial."

"Our trial is designed to be statistically robust and also yield early significant data. The trial has been designed to appeal to potential partners and help steer the Phase 3 clinical trial design. I have been very impressed with our dealings with the Orion team in the last few months. We look forward to working with our new partner and reporting on the inevitable progress."

Ronald Openshaw, Chief Executive Officer of Simbec-Orion said, "We are pleased to prevail in Imugene's stringent selection process and look forward to driving this important clinical trial. We will ensure a combination of rigour and efficiency and are adamant about achieving on timelines and quality of data that should satisfy the US FDA."

**About Imugene:**

Imugene (ASX; IMU) is a clinical stage immuno-oncology company developing HER-2+ gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER-2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase 1 study in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.

**About Simbec-Orion:**

Simbec-Orion is a full service CRO operating from first in human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. Simbec-Orion has expertise in all drug types, dosage forms and delivery mechanisms and in later stage development has particular expertise in oncology, rare and orphan diseases. Simbec-Orion supports its clients with its own in-house full service central laboratories, pharmacovigilance, data management and statistics, pharmacy, medical management. Simbec-Orion's corporate headquarters are located in Merthyr Tydfil, Wales operating in Australia via its wholly owned subsidiary Orion Clinical Services (Australia) Ltd with offices in Victoria, Australia.

**For more information, please contact:****Imugene:****Charles Walker  
Managing Director**

Tel: +61 (0) 4 5044 6990  
cwalker[at]imugene.com  
[www.imugene.com](http://www.imugene.com)

**Paul Hopper  
Executive Chairman**

Tel: +61 406 671 515 (Australia)  
receptogen[at]earthlink.net

**Media contact:**

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333  
rudim[at]monsoon.com.au

**Simbec-Orion:****Ronald Openshaw  
Chief Executive Officer**

Tel: +44 (0)1753 578080  
[www.simbec.com](http://www.simbec.com)  
[www.orioncro.com](http://www.orioncro.com)

**Albert Shen  
Clinical Operations Manager**

Tel: +61 (3) 9847 6830  
[www.simbec.com](http://www.simbec.com)  
[www.orioncro.com](http://www.orioncro.com)

**Media contact:**

Mary-Jane Elliott  
Ivar Milligan  
Consilium Strategic Communications  
Tel: +44 (0)203709 5700  
SimbecOrion@consilium-comms.com